GARDEN (Global Hematological Rare Diseases Alliance)/LinkedIn
May 23, 2026, 14:42
How Should Evidence Be Interpreted in Modern Hemophilia Care? – GARDEN
GARDEN (Global Hematological Rare Diseases Alliance) shared a post on LinkedIn:
“How should evidence be interpreted in modern hemophilia care?
In this new contribution from the GARDEN editorial series, Prof. Cedric Hermans explores the methodological debate behind international hemophilia guidelines, examining the balance between randomized clinical trials, real-world evidence, and patient-centered decision-making.
A critical reflection on how evidence shapes clinical practice, access to care, and the future of hemophilia management.”
Stay updated with Hemostasis Today.
-
Aug 31, 2026, 14:03Adil Aftab: Anticoagulation in CKD – Key Updates from the 2026 ESC Guidelines
-
Aug 31, 2026, 14:01Isa Oboirien: Why Might Factor XI Inhibition Work Differently in Stroke and ACS?
-
Aug 31, 2026, 13:55Mike Morrissey: Advancing Europe’s Cardiovascular Health Agenda at ESC Congress 2026
-
Aug 31, 2026, 13:44Penilla Gunther: Patient Voices Take Center Stage in Cardiovascular Prevention at ESC Congress 2026
-
Aug 31, 2026, 13:42Mohamed Saleh Gomaa: Master the Latest in PE Management
-
Aug 31, 2026, 13:38Lyn Kleinbach-Reilly: A New Standard for Coagulation Testing in Neonatal Care
-
Aug 31, 2026, 13:36Rafael Gomes: Can Prasugrel Replace Ticagrelor in ACS Treatment?
-
Aug 31, 2026, 05:35Does LDL Cholesterol Influence VTE Risk? – Ordo Fraterna Fibonacci
-
Aug 31, 2026, 05:19Tania Ahuja: Apixaban in Abdominal Transplant Patients